Edwards Lifesciences Expands Structural Heart Portfolio With Acquisitions of JenaValve and Endotronix
DAIC
JULY 29, 2024
As the pioneer in valve innovation for more than 60 years, Edwards believes it is uniquely positioned to lead this next frontier of aortic valve disease treatment. A CMS national coverage determination is expected in early 2025. Edwards expects minimal revenue contribution from these acquisitions in 2025.
Let's personalize your content